| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
17a-Hydroxypregnenolone targets steroidogenic enzymes and steroid hormone receptors. As a precursor hormone, it serves as a substrate for various steroidogenic enzymes including 17α-hydroxylase, 17,20-lyase, and 3β-hydroxysteroid dehydrogenase, which convert it into downstream steroid hormones. It can also function as a neuroactive steroid, directly modulating neurotransmitter receptors. The compound acts as a precursor for cortisol and sex steroids.
|
|---|---|
| ln Vitro |
In vitro, 17a-Hydroxypregnenolone serves as a substrate for steroidogenic enzymes in adrenal and gonadal cells. It is converted by 17,20-lyase to dehydroepiandrosterone (DHEA), which is then converted to androstenedione and downstream androgens and estrogens. It is also converted by 3β-hydroxysteroid dehydrogenase to 17α-hydroxyprogesterone, a precursor for cortisol and aldosterone. As a neuroactive steroid, it can modulate GABAA receptors and other neurotransmitter receptors.
|
| ln Vivo |
In vivo, 17a-Hydroxypregnenolone is produced in the adrenal cortex and gonads as part of the steroid biosynthesis pathway. It serves as a critical intermediate in the production of cortisol, aldosterone, and sex steroids. As a neuroactive steroid, it can affect brain function. It is transported in the blood and taken up by target tissues where it is converted to active steroid hormones. Its levels are regulated by ACTH and other hormones.
|
| Enzyme Assay |
Non-cellular enzyme/receptor binding assay protocols for 17a-Hydroxypregnenolone involve measuring its conversion by steroidogenic enzymes. Enzyme activity assays use purified enzymes (e.g., CYP17A1, 3β-HSD) and radiolabeled or HPLC-detectable substrates. The conversion of 17a-hydroxypregnenolone to downstream products is measured. Receptor binding studies can be performed using SPR or radioligand binding assays for neuroactive steroid receptors.
|
| Cell Assay |
Cellular assay protocols for 17a-Hydroxypregnenolone involve treating steroidogenic cells (e.g., adrenal or gonadal cell lines) with the compound. Steroid production is measured by ELISA, RIA, or LC-MS/MS. The effects of 17a-hydroxypregnenolone on cell signaling and gene expression can be assessed. As a neuroactive steroid, its effects on neuronal cells can be evaluated by measuring receptor modulation.
|
| Animal Protocol |
In vivo animal experiment protocols for 17a-Hydroxypregnenolone involve administering the compound to rodents. Administration routes may include injection or oral dosing. Endpoints include measurement of steroid hormone levels in blood and tissues, assessment of neuroactive steroid effects on behavior or neurological function, and evaluation of endocrine function. Tissue samples are collected for biochemical analysis.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 17a-Hydroxypregnenolone have been characterized as an endogenous steroid hormone. It is produced endogenously and circulates in the blood. It has a relatively short half-life and is metabolized by steroidogenic enzymes. As a small molecule (MW 332.48 g/mol), it is expected to have reasonable bioavailability. It is transported in the blood bound to carrier proteins such as albumin and corticosteroid-binding globulin.
|
| Toxicity/Toxicokinetics |
Toxicity of 17a-Hydroxypregnenolone has not been extensively studied as a pharmacological agent, as it is an endogenous compound. However, as a steroid precursor, high levels may affect endocrine function. Standard toxicological evaluation would include assessments of endocrine, reproductive, and metabolic effects. The compound is for research use only.
|
| Additional Infomation |
17α-Hydroxypregnenolone is a hydroxypregnenolone with an α-hydroxy group at position 17. It is a metabolite in both humans and mice. It is a hydroxypregnenolone, a 17α-hydroxy steroid, a 3β-hydroxy-Δ(5)-steroid, a 17α-hydroxy-C21-steroid, and a tertiary α-hydroxy ketone.
It has been reported that 17α-hydroxypregnenolone exists in Homo sapiens, and relevant data are available for reference. 17α-Hydroxypregnenolone is an endogenous steroid hormone synthesized by hydroxylation of pregnenolone. It can function as a neuroactive steroid and as a precursor hormone for progestins, mineralocorticoids, glucocorticoids, androgens, estrogens, and neuroactive steroids. It is a 21-carbon steroid derived from pregnenolone via 17α-hydroxylase. It is an intermediate in the δ-5 pathway of gonadal steroid hormone and adrenocortical hormone biosynthesis. 17a-Hydroxypregnenolone (CAS: 387-79-1) has a molecular formula of C21H32O3 and a molecular weight of 332.48 g/mol. It is an endogenous steroid hormone synthesized by hydroxylation of pregnenolone. It functions as a neuroactive steroid and as a precursor hormone for progestins, mineralocorticoids, glucocorticoids, androgens, estrogens, and neuroactive steroids. It is a metabolite of pregnenolone and a precursor for cortisol and sex steroids. Purity is typically ≥95%. Storage: 2-8°C. This product is for research use only. |
| Molecular Formula |
C₂₁H₃₂O₃
|
|---|---|
| Molecular Weight |
332.48
|
| Exact Mass |
334.25
|
| CAS # |
387-79-1
|
| PubChem CID |
91451
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
468.1±40.0 °C at 760 mmHg
|
| Melting Point |
273℃
|
| Flash Point |
251.0±23.8 °C
|
| Vapour Pressure |
0.0±2.6 mmHg at 25°C
|
| Index of Refraction |
1.540
|
| LogP |
3.46
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
24
|
| Complexity |
596
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
CC(=O)[C@]1(CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@@]21C)O)O
|
| InChi Key |
JERGUCIJOXJXHF-TVWVXWENSA-N
|
| InChi Code |
InChI=1S/C21H32O3/c1-13(22)21(24)11-8-18-16-5-4-14-12-15(23)6-9-19(14,2)17(16)7-10-20(18,21)3/h4,15-18,23-24H,5-12H2,1-3H3/t15-,16+,17-,18-,19-,20-,21-/m0/s1
|
| Chemical Name |
1-[(3S,8R,9S,10R,13S,14S,17R)-3,17-dihydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl]ethanone
|
| Synonyms |
17aHydroxypregnenolone; 17a Hydroxypregnenolone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~8.33 mg/mL (~25.05 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 0.83 mg/mL (2.50 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.3 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.83 mg/mL (2.50 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.3 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 0.83 mg/mL (2.50 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0077 mL | 15.0385 mL | 30.0770 mL | |
| 5 mM | 0.6015 mL | 3.0077 mL | 6.0154 mL | |
| 10 mM | 0.3008 mL | 1.5038 mL | 3.0077 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
